Humacyte Inc (NASDAQ:HUMA) stock surged 21% after the company announced that its Symvess product received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and patients receiving care at Department of Defense (DOD) and U.S. Department of Veterans Affairs facilities. This listing provides these federal agencies with direct access to the company’s bioengineered human tissue product.
Symvess, described as an acellular tissue engineered vessel, received FDA approval for extremity vascular trauma indication in December 2024. The product is part of Humacyte’s commercial-stage biotechnology platform that develops universally implantable, bioengineered human tissue.
"We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families," said Dr. Laura Niklason, President and CEO of Humacyte. "We have received positive feedback in our interactions with a number of DOD hospitals, and we look forward to making Symvess available to more patients in need."
The company noted that for uses beyond the FDA-approved extremity vascular trauma indication, the acellular tissue engineered vessel remains an investigational product that has not received regulatory approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.